A versatile research and development leader with deep antimicrobial experience and broad drug development expertise. Passionate about building and nurturing, dynamic, high-performing teams to translate cutting-edge technologies into new products and therapeutics. I have over 20 years’ experience in antimicrobial drug discovery, structure-based drug design, medicinal chemistry, structural biology, biochemistry from concept to lead molecule. I can build cross-functional teams and provide an essential link between scientists, collaborators and stakeholders to deliver products.I built a successful career as a tenured PI at Monash University (Australia) before choosing to transition to industry to pursue a strong desire to deliver real world solutions. I am widely published with >85 research papers and >130 structures generated in the protein databank. I have developed broad communications skills with experience in dilutive and non-dilutive funding applications, presentations to CEO, boards, research & development committees and at international scientific conferences. As a senior member of an Australian ‘Group of 8’ University, I held multiple critical leadership roles that spanned academic departments, discovery centres and cross-faculty positions, leveraging an extensive skillset in strategy, operations and management.In my previous position, I established and led a global structure-based drug design program that delivered a new compound class to the global product developer. I raised $AUD12M, built and led a matrixed team (academic, VC and philanthropic stakeholders; chemistry, biology, DMPK, CRO scientists; product developers). The outcomes of this program were target ID, MoA characterization and target validation; hit discovery > hit-to-lead optimization; compound design and development; assay development and transition to high-throughput and computational screens; DMPK optimization; engagement with global product developer for transition to their pipeline.